================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
----------
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 31, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ............. to ..............
Commission File Number 000-27592
SCANTEK MEDICAL INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 84-1090126
------------------------------- -------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
321 Palmer Road, Denville, New Jersey 07834
(973) 366-5250
------------------------------------------------------
(Address and telephone number, including area code, of
registrant's principal executive office)
(Former name, former address and former fiscal year, if changed
since last report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes X No
----- -----
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
At January 31, 1999, there were 17,945,200 shares of Common Stock, $.001
par value, outstanding.
================================================================================
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC.
INDEX
Page
-----
<S> <C> <C>
Part I. Financial Information 1
Item 1. Financial Statements
Consolidated Balance Sheets as of
December 31, 1998 (unaudited) and
June 30, 1998 2
Consolidated Statements of Operations for the Six Months and
Three Months Ended December 31, 1998 and 1997 (unaudited) and
for the Period June 10, 1988 (Date of Formation) through
December 31, 1998 3 - 4
Consolidated Statements of Stockholders'
Equity (Deficiency) for the Period June 10, 1988 (Date
of Formation) through December 31, 1998
(unaudited) 5 - 10
Consolidated Statements of Cash Flows for the Six Months Ended
December 31, 1998 and 1997 (unaudited) and for the Period
June 10, 1988 (Date of Formation)
through December 31, 1998 11 - 12
Notes to Financial Statements (unaudited) 13 - 15
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 16 - 23
Part II. Other Information
Item 1. Legal Proceedings 24
Item 6. Exhibits and Report on Form 8-K 24
Signatures 25
</TABLE>
<PAGE>
PART I. Financial Information
Item 1. Financial Statements
Certain information and footnote disclosures required under generally
accepted accounting principles have been condensed or omitted from the following
consolidated financial statements pursuant to the rules and regulations of the
Securities and Exchange Commission. It is suggested that the following
consolidated financial statements be read in conjunction with the year-end
financial statements and notes thereto included in the Company's Registration
Statement on Form 10-KSB for the year ended June 30, 1998.
The results of operations for the six months ended December 31, 1998, are
not necessarily indicative of the results to be expected for the entire fiscal
year or for any other period.
-1-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED BALANCE SHEETS
ASSETS
December 31, June 30,
1998 1998
------------ ----------
(Unaudited)
Current Assets:
<S> <C> <C>
Cash $ 32,278 $ 55,929
Marketable securities 641,678 2,295,253
Inventory 159,132 -
Due from licensees 601,900 726,900
Prepaid expenses 102,674 23,517
---------- ---------
Total Current Assets 1,537,662 3,101,599
========== =========
Property and equipment - net 1,885,247 822,043
Marketable securities - non-current 80 901,520
Other assets - net 367,054 383,275
----------- ----------
TOTAL ASSETS $ 3,790,043 $5,208,437
=========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)
Current Liabilities:
Short-term debt $ 400,000 $ 100,000
Current portion - deferred income - 752,500
Note payable to officer 805,993 621,993
Accounts payable 1,356,643 266,869
Accrued interest 102,327 110,470
Accrued salaries 966,119 841,119
Accrued expenses 83,499 65,785
---------- ----------
Total Current Liabilities 3,714,581 2,758,736
========== ==========
Long-term debt 888,006 888,006
---------- ----------
Total Liabilities 4,602,587 3,646,742
========== ==========
Commitments and Contingencies
Stockholders' Equity (Deficiency):
Preferred stock, par value $.001
per share - authorized 5,000,000
shares; none issued - -
Common stock, par value $.001 per
share - authorized 45,000,000;
outstanding 17,945,200 and 17,220,200 17,945 17,220
Additional paid-in-capital 3,201,174 2,993,206
Unrealized gain on marketable
securities 66,601 2,621,616
Deficit accumulated during development
stage (4,098,264) (4,070,347)
Total Stockholders' Equity (Deficiency) ( 812,544) 1,561,695
----------- ----------
TOTAL LIABILITIES AND STOCKHOLDERS'
EQUITY (DEFICIENCY) $3,790,043 $5,208,437
========== ==========
</TABLE>
See notes to consolidated financial statements.
-2-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
For the
Period
June 10, 1988
Six Months Ended Three Months Ended (Date of Formation)
December 31, December 31, Through
1998 1997 1998 1997 December 31, 1998
---------------- ----------- ---------- ----------- ------------------
<S> <C> <C> <C> <C> <C>
Revenues:
Net sales $ 127 775 $ - $ 32,983 - $ 127,775
License fees 752,500 - 252,500 - 2,554,082
--------- -------- -------- -------- ---------
Total Revenues 880,275 - 285,483 - 2,681,857
--------- -------- -------- -------- ---------
Costs and Expenses:
Cost of sales 97,809 - 40,394 - 97,809
General and adminis-
trative expenses 392,604 334,728 220,266 167,431 3,832,279
Amortization and
depreciation 111,280 39,077 88,688 19,981 817,523
Research and
development 217,016 149,310 135,625 75,200 1,787,796
Interest expense 89,618 92,069 49,079 45,398 752,572
--------- ------- --------- ------- ---------
Total Costs and
Expenses 908,327 615,184 534,052 308,010 7,287,979
--------- ------- ------- ------- ---------
Net Operating (Loss) ( 28,052) (615,184) (248,569) (308,010) (4,606,122)
---------- --------- --------- -------- -----------
</TABLE>
(continued)
See notes to consolidated financial statements.
-3-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF OPERATIONS (continued)
(Unaudited)
<TABLE>
<CAPTION>
For the
Period
June 10, 1988
Six Months Ended Three Months Ended (Date of Formation)
December 31, December 31, Through
1998 1997 1998 1997 December 31, 1998
---------------- ----------- ---------- ----------- ------------------
<S> <C> <C> <C> <C> <C>
Other income:
Interest and
dividends 135 $ 16,693 $ 16 $ 6,712 $ 51,354
Consulting - - - - 15,000
Gain on sale of
marketable
securities - - - - 414,604
Miscellaneous - 5,789 - (2,397) 26,900
--------- -------- --------- ------- ---------
Total Other Income 135 22,482 16 4,315 507,858
--------- -------- --------- ------- ---------
Net (Loss) $ ( 27,917) $ (592,702) $ (248,553) $ (303,695) $(4,098,264)
=========== ========== ========== ========== ===========
(Loss) per common
share - basic $ - $(.03) $(.01) $(.02)
====== ===== ===== =====
(Loss) per common
share - diluted $ - $(.03) $(.01) $(.02)
====== ===== ===== =====
Weighted average number
of common shares
outstanding - basic 17,366,033 17,220,200 17,511,867 17,220,200
========== ========== ========== ==========
Weighted average number
of common shares
outstanding -
diluted 17,482,790 17,945,761 17,511,867 17,682,748
========== =========== ========== ==========
</TABLE>
See notes to consolidated financial statements.
-4-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY)
(Unaudited)
(Deficit)
Unrealized Accumulated
Common Stock Treasury Stock Additional Gain (loss) During the
------------------- --------------- Paid-In on Marketable Development
Shares Amount Shares Amount Capital Securities Stage Total
-------- ------ ------ ------ ------- ----------- ------------- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Original Capitali-
zation:
Sale of stock ($.023
per share) 2,000,000 $ 2,000 - $ - $ 44,094 $ - $ - $ 46,094
Issuance of
options for
services ren-
dered (valued
at .10 per share) 5,000 5,000
Net (loss)
June 10, 1988
(Date of For-
mation) through
June 30, 1991 (18,751) (18,751)
---------- ------- ------ ------- -------- -------- ---------- -----------
Balance June 30,
1991 2,000,000 $ 2,000 - $ - $ 49,094 $ - (18,751) 32,343
.7 for 1 reverse
stock split (600,000) (600) 600 -
Donated stock to
treasury 500,000 - -
Issuance of
stock to acquire
subsidiary ($.006
per share) 7,100,000 7,100 - 92,900 100,000
Sale of treasury
stock ($2.50 per
share) (18,000) 45,000 45,000
Treasury stock
exchanged for
services rendered
(valued at $.023
per share) (433,000) 10,000 10,000
Net (loss), June
30, 1992 (485,314) (485,314)
---------- ------- ------ ------- -------- -------- ---------- -----------
Balance, June 30,
1992 8,500,000 $ 8,500 49,000 - 197,594 - (504,065) (297,971)
</TABLE>
See notes to consolidated financial statements. (Continued)
-5-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) (Continued)
(Unaudited)
(Deficit)
Unrealized Accumulated
Common Stock Treasury Stock Additional Gain (loss) During the
------------------- --------------- Paid-In on Marketable Development
Shares Amount Shares Amount Capital Securities Stage Total
-------- ------ ------ ------ ------- ----------- ------------- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Treasury stock
exchanged for
services rendered
(valued at $0.125
per share) (49,000) 6,125 6,125
Issuance of stock
for professional
services rendered
(valued at $.25 to
$.50 per share) 1,450,000 1,450 411,050 412,500
Issuance of stock
for contract
release (valued at
$1.00 per share) 35,000 35 34,965 35,000
Net (loss), June
30, 1993 (924,969) (924,969)
---------- ------- ------ ------- -------- -------- ---------- -----------
Balance, June 30,
1993 9,985,000 9,985 - - 649,734 - (1,429,034) (769,315)
Issuance of call-
able warrants for
services rendered
(valued at $.125
per share) 15,625 15,625
Issuance of stock
in connection
with bridge loan
financing (issued
at $1.00 per
share) 37,200 37 37,163 37,200
Net (loss), June
30, 1994 (969,408) (969,408)
---------- ------- ------ ------- -------- -------- ---------- -----------
Balance, June 30,
1994 10,022,200 10,022 - - 702,522 - (2,398,442) (1,685,898)
(Continued)
</TABLE>
See notes to consolidated financial statements.
-6-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) (Continued)
(Unaudited)
(Deficit)
Unrealized Accumulated
Common Stock Treasury Stock Additional Gain (loss) During the
------------------- --------------- Paid-In on Marketable Development
Shares Amount Shares Amount Capital Securities Stage Total
-------- ------ ------ ------ ------- ----------- ------------- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Issuance of stock
in connection with
bridge loan finan-
cing (issued at
$1.00 per share) 12,000 12 11,988 12,000
Issuance of stock
for services ren-
dered (valued at
$.125 per share) 621,250 621 77,035 77,656
Net (loss), June
30, 1995 (736,267) (736,267)
---------- ------- ------ ------- -------- -------- ---------- -----------
Balance - June 30,
1995 10,655,450 10,655 - - 791,545 - (3,134,709) (2,332,509)
Issuance of stock
for accrued sal-
aries (valued at
$.10 per share) 4,550,000 4,550 450,450 455,000
Notes payable con-
versions to
common stock
(at $1.00 per
share) 151,084 151 150,933 151,084
Issuance of stock
for services ren-
dered (at $.60
per share) 433,666 434 273,232 273,666
Issuance of options
for services ren-
dered (at $.30
per share) 45,000 45,000
Net unrealized gain
on marketable
securities 364,500 364,500
Net (loss), June
30, 1996 (816,716) (816,716)
---------- ------- ------ ------- -------- -------- ---------- -----------
Balance - June 30,
1996 15,790,200 15,790 - - 1,711,160 364,500 (3,951,425) (1,859,975)
See notes to consolidated financial statements.
</TABLE>
-7-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) (Continued)
(Unaudited)
(Deficit)
Unrealized Accumulated
Common Stock Treasury Stock Additional Gain (loss) During the
------------------- --------------- Paid-In on Marketable Development
Shares Amount Shares Amount Capital Securities Stage Total
-------- ------ ------ ------ ------- ----------- ------------- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Issuance of stock in
connection with pri-
vate placement
offering (issued at
$1.00 per share) 1,070,000 1,070 1,068,930 1,070,000
Issuance of stock
for professional
services rendered
(at $.167 to $1.00
per share) 72,500 73 22,427 22,500
Issuance of stock in
lieu of payment on
equipment (at $1.00
per share) 100,000 100 99,900 100,000
Stock options exer-
cised ($.10 to
$.375 per share) 170,000 170 27,830 28,000
Issuance of stock
for rent (at $2.01
per share) 17,500 17 35,179 35,196
Net unrealized gain
on marketable
securities 5,202,115 5,202,115
Net (loss) - June 30,
1997 (773,723) (773,723)
---------- ------- ------ ------- -------- -------- ---------- -----------
Balance, June 30,
1997 17,220,200 17,220 - - 2,965,426 5,566,615 (4,725,148) 3,824,113
See notes to consolidated financial statements.
</TABLE>
-8-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) (Continued)
(Unaudited)
(Deficit)
Unrealized Accumulated
Common Stock Treasury Stock Additional Gain (loss) During the
------------------- --------------- Paid-In on Marketable Development
Shares Amount Shares Amount Capital Securities Stage Total
-------- ------ ------ ------ ------- ----------- ------------- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Issuance of warrants
for services ren-
dered (at $ .55 to
$1.125 per share) 27,780 27,780
Net unrealized (loss)
on marketable
securities (2,944,999) (2,944,999)
Net earnings -
June 30, 1998 654,801 654,801
---------- ------- ------ ------- -------- --------- ---------- ---------
Balance, June 30,
1998 17,220,200 $ 17,220 - $ - $2,993,206 2,621,616 $(4,070,347) $1,561,695
Issuance of stock
for salaries (at
.1875 per share) 350,000 350 65,275 65,625
Sale of common stock
(at .3333 per share) 300,000 300 99,700 100,000
Issuance of stock in
connection with
loan financing
(at .1875 per share) 75,000 75 13,988 14,063
Issuance of warrants
for services ren-
dered (at $ .1875 to
$1.125 per share) 29,005 29,005
</TABLE>
See notes to consolidated financial statements.
-9-
<PAGE>
<TABLE>
<CAPTION>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIENCY) (Continued)
(Unaudited)
(Deficit)
Unrealized Accumulated
Common Stock Treasury Stock Additional Gain (loss) During the
------------------- --------------- Paid-In on Marketable Development
Shares Amount Shares Amount Capital Securities Stage Total
-------- ------ ------ ------ ------- ----------- ------------- -----
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Net unrealized (loss)
on marketable
securities (2,555,015) (2,555,015)
Net loss -
December 31, 1998 (27,917) (27,917)
---------- ------- ------ ------ ---------- --------- ----------- -----------
Balance,
December 31, 1998 17,945,200 $17,945 $ - $ - $3,201,174 $ 66,601 $(4,098,264) $ (812,544)
========== ======= ====== ====== ========== ========= =========== ===========
</TABLE>
See notes to consolidated financial statements.
-10-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
For the Period
June 10, 1988
Six Months Ended December 31, (Date of For-
---------------------------- mation) through
1998 1997 December 31, 1998
--------- ---------- -----------------
<S> <C> <C> <C>
Cash flows from operating
activities:
Net (loss) $ (27,917) $ (592,702) $(4,098,264)
Adjustments to reconcile net
(loss) to net cash used in
operating activities:
Depreciation and amortization 111,280 39,077 817,522
Net gain on sale of
marketable securities (5,789) (414,604)
Non-employee stock based
compensation 14,063 -- 859,637
Non-cash officers compensation 65,625 -- 522,875
Other non-cash items 29,005 -- 328,765
Changes in operating
assets and liabilities 342,175 162,812 978,114
----------- ----------- -----------
Net Cash Provided by (Used
in) Operating Activities 534,231 (396,602) (1,005,955)
----------- ----------- -----------
Cash flows from investing
activities:
Proceeds from sale of
marketable securities -- 168,240 1,191,313
Purchases of patents -- -- (76,069)
Organization costs -- -- (199,672)
Purchase and deposits
of equipment (1,140,680) (155,330) (1,990,109)
Purchase of marketable
securities (123,282) (777,534)
----------- ----------- -----------
Net Cash (Used in)
Investing Activities (1,140,680) (110,372) (1,852,071)
----------- ----------- -----------
Cash flows from financing activities:
Proceeds from borrowings 300,000 -- 1,903,208
Proceeds from officer loans 184,000 -- 807,993
Repayment of officer loans -- (2,000)
Repayment of notes (1,202) (33,806) (1,107,991)
Proceeds from the sale of
options -- 28,000
Proceeds from sale of common
and treasury stock 100,000 -- 1,261,094
----------- ----------- -----------
Net Cash Provided by (Used
in) Financing Activities 582,798 (33,806) 2,890,304
----------- ----------- -----------
Net Increase (decrease) in Cash (23,651) (540,780) 32,278
Cash - beginning of period 55,929 918,393 --
----------- ----------- -----------
Cash - end of period $ 32,278 $ 377,613 $ 32,278
=========== =========== ===========
</TABLE>
See notes to consolidated financial statements.
-11-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
For the Period
June 30, 1988
Six Months Ended December 31, (Date of For-
----------------------------- mation) through
1998 1997 December 31, 1998
------------- -------------- -----------------
<S> <C> <C> <C>
Changes in Operating Assets
and Liabilities Consist of:
(Increase) in inventory $ (159,132) $ $ (159,132)
(Increase) decrease in
due from licensees 200,000 (400,000) (101,900)
(Increase) decrease in
prepaid expenses (79,157) 2,201 (102,674)
(Increase) in marketable
securities - non-current -- -- (300,000)
(Increase) in other assets (92,583) (62,017) (697,723)
Increase in accounts
payable and accrued
expenses 1,225,547 122,628 2,616,224
Increase (decrease) in
deferred income (752,500) 500,000 (276,582)
(Decrease) in accrued
franchise taxes -- -- (99)
------------ ----------- -----------
$ 342,175 $ 162,812 $ 978,114
============ =========== ===========
Supplementary information:
Cash paid during the year for:
Interest $ 90,668 $ 116,616 $ 540,555
============ =========== ===========
Income taxes $ -- $ -- $ --
============ =========== ===========
Non-cash investing activities:
Debt incurred for asset
transfer agreement of
patents $ -- $ -- $ 600,000
============ =========== ===========
Acquisition of subsidiary
for common stock $ -- $ -- $ 100,000
============ =========== ===========
Acquisition of mar-
ketable securities in
connection with
licensing agreement $ -- $ -- $ 276,582
============ =========== ===========
Unrealized gain (loss)
on marketable
securities $ (1,171,772) $ (337,066) $ 66,601
============ =========== ===========
Deposit on equipment
for common stock $ -- $ -- $ 100,000
============ =========== ===========
Non-Cash Financing Activities:
Conversion of long-term
debt to common stock $ -- $ -- $ 121,000
============ =========== ===========
Other Non-Cash Activities:
Conversion of accounts
payable and accrued
expenses to common stock $ 14,063 $ -- $ 914,865
============ =========== ===========
Conversion of accounts
payable to stock
options $ -- $ -- $ 50,000
============ =========== ===========
Conversion of accounts
payable to warrants $ 29,005 $ -- $ 86,628
============ =========== ===========
Conversion of accounts
payable to treasury
stock $ -- $ -- $ 16,125
============ =========== ===========
Conversion of accrued
officers' salaries to
common stock $ 65,625 $ -- $ 522,875
============ =========== ===========
</TABLE>
See notes to consolidated financial statements.
-12-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Planned principal operations of Scantek Medical Inc. (the "Company" or
"Scantek") have commenced. The Company manufactured and distributed units of the
BreastCare(TM) device to customers in Brazil, Uruguay, Argentina and Paraguay
during the first and second quarters of its current fiscal year. The Company
expects its manufacturing and distribution operations to be in full operation
during the first quarter of calendar 1999. The Company's continued existence is
dependent not only upon cash flow to be derived from operations during 1999 but
upon its ability to obtain needed working capital through additional equity
and/or debt financing. Management is actively seeking additional capital to
ensure the continuation of its development and marketing activities as well as
its manufacturing and distribution operations; accordingly, the Company is
considered a development stage company.
The consolidated balance sheet as of December 31, 1998, consolidated
statements of operations and cash flows for the six months ended December 31,
1998 and 1997, and for the period June 10, 1988 (Date of Formation) through
December 31, 1998 have been prepared by the Company and are unaudited. In the
opinion of management, all adjustments (consisting of normal recurring
adjustments) necessary to present fairly the financial position, results of
operations and cash flows for all periods presented have been made. Certain
items in the December 31, 1997 financial statements have been reclassified to
conform to December 31, 1998 classifications. The information for June 30, 1998
was derived from audited financial statements.
Receivable Recognition - Receivables due from licensees are recognized
either upon the acceptance of the equipment by the licensee or upon the signing
of the definitive agreement.
License Revenue Recognition - Revenues will be recognized in income when
the licensees commence operations, since substantial performance is presumed to
occur at that point.
2. (LOSS) PER SHARE
Basic (loss) per common share is computed using the weighted average number
of common shares outstanding during the period. Diluted (loss) per common share
is computed using the weighted average number of common shares and common stock
equivalent shares outstanding during the period. Loss per share for the quarter
ended December 31, 1998 has been restated to conform to the provisions of SFAS
128.
-13-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
2. (LOSS) PER SHARE (Continued)
<TABLE>
<CAPTION>
Six Months Ended Three Months Ended
---------------------------- ----------------------------
December 31, December 31,
---------------------------- ----------------------------
1998 1997 1998 1997
--------- --------- ---------- ------------
<S> <C> <C> <C> <C>
Basic:
Net (loss) $ (27,917) $ (592,702) $ (248,553) $ (303,695)
Weighted average
shares out-
standing 17,366,033 17,220,200 17,511,867 17,220,200
(Loss) per
share - basic $ -- $ (.03) $ (.01) $ (.02)
Diluted:
Net (loss) $(27,917) $(59,702) $(248,553) $(303,695)
Weighted average
shares out-
standing 17,366,033 17,220,200 17,511,867 17,220,200
Incremental shares 116,757 725,561 -- 462,548
------------ ------------ ------------ ------------
Adjusted weighted
average shares out-
standing 17,482,790 17,945,761 17,511,867 17,682,748
============ ============ ============ ============
(Loss) per share-
diluted $ -- $ (.03) $ (.01) $ (.02)
3. MARKETABLE SECURITIES
Esti-
mated Gross Gross un-
Fair Unrealized realized
Cost Value Gains Losses
------------ ------------ ------------ -------------
<S> <C> <C> <C> <C>
December 31, 1998:
Marketable Securities
- Current
Common stock $ 275,157 $ 641,678 $ 1,498,000 $ 1,131,479
Marketable Securities
- Non-current
Warrants $ 300,000 $ 80 $ -- $ 299,920
June 30, 1998:
Marketable Securities
- Current
Common stock $ 275,157 $ 2,295,253 $ 2,020,096 $ --
Marketable Securities
- Non-current
Warrants $ 300,000 $ 901,520 $ 601,520 $ --
</TABLE>
-14-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
4. INVENTORIES
Inventories consist of the following:
December 31, June 30,
1998 1998
----------- -------
Raw materials $ 39,445 $ --
Work-in-process 2,800 --
Finished goods 116,887 --
-------- ------
$159,132 $ --
======== =======
5. EQUIPMENT
Equipment consists of the following:
December 31, June 30,
1998 1998
------------ ----------
Equipment $1,952,245 $ 101,565
Furniture and fixtures 27,489 27,489
Deposit on equipment -- 710,000
Leasehold improvements 16,525 16,525
---------- ----------
1,996,259 855,579
Less accumulated
depreciation 111,012 33,536
---------- ----------
Net Equipment $1,885,247 $ 822,043
========== ==========
6. OTHER ASSETS
Other assets consist of the following:
December 31, June 30,
1998 1998
----------- ----------
Patent costs $676,069 $676,069
Long-term portion of amount
due from licensees -- 75,000
Security deposits 13,125 13,125
Other 184,698 92,114
-------- --------
873,892 856,308
Less accumulated amortization 506,838 473,033
-------- --------
Other Assets - Net $367,054 $383,275
======== ========
7. INCOME TAXES
Financial Accounting Standards Board Statement No. 109, "Accounting for
Income Taxes" (SFAS 109), provides for the recognition of deferred assets
subject to a valuation allowance. At June 30, 1996, the Company established a
valuation allowance equal to the full amount of the tax effect of the net
operating loss carryforward. At December 31, 1998, the Company has provided no
deferred taxes on the unrealized gain on marketable securities after off-setting
the net operating loss carryforward, which offsets any gain.
-15-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
-----------------------------------
Results of Operations
- ---------------------
The following table sets forth for the periods indicated, the percentage
increase or (decrease) of certain items included in the Company's consolidated
statement of operations:
% Increase (Decrease) from Prior Period
---------------------------------------
Six Months Ended Three Months Ended
December 31, 1998 December 31, 1998
compared with 1997 Compared with 1997
------------------ -------------------
General and administrative expense 17.3% 31.6%
Amortization and depreciation 184.8 343.9
Research and development 45.3 80.4
Interest expense (2.7) (8.2)
Net (loss) (95.3) (18.2)
Six Months 1998 vs. Six Months 1997 and Three Months 1998 vs. Three Months 1997
- --------------------------------------------------------------------------------
Revenues
- --------
Net sales increased to $127,775 during the six months ended December 31,
1998 from $0 during the six months ended December 31, 1997 as the Company
commenced initial shipments of its BreastCare(TM) device during the first
quarter of its current fiscal year. The Company expects the demand for its
product to continue with full operations commencing in the first quarter of
calendar 1999.
License fee revenue increased to $752,500 during the six months ended
December 31, 1998 from $0 during the six months ended December 31, 1997 as the
Company recognized the deferred license fee funds for Sandell and D-Lanz.
Sandell operations commenced during the first quarter of its current fiscal
year, and D-Lanz signed an agreement with Sandell in the second quarter for
Sandell to be its exclusive distributor.
Net sales increased to $32,983 during the three-month period ended December
31, 1998, and license fee revenue increased to $252,500 for the three months
ended December 31, 1997 for primarily the same reasons set forth in the
six-month analysis.
Cost of Sales
- -------------
Cost of sales increased $97,809 and $40,394 during the six months and three
months ended December 31, 1998 from $0 during the six months and three months
ended December 31, 1997 primarily due to the same reasons above.
-16-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)
--------------------------------------------------
General and Administrative Expenses
-----------------------------------
General and administrative expenses increased 17.3% for the six-month
period ending December 31, 1998 as compared with the six-month period ended
December 31, 1997. This increase is primarily due to increases in consulting,
insurance and travel expense offset in part by decreased legal fees.
General and administration expenses increased 31.6% to $220,266 during the
three months ended December 31, 1998 compared to $167,431 during the three
months ended December 31, 1997 for principally the same reasons set forth in the
six-month analysis.
Amortization and Depreciation Expense
-------------------------------------
Amortization and depreciation expense was $111,280 for the six months ended
December 31, 1998 as compared to $39,077 for the six months ended December 31,
1997. The 184.8% increase was attributable to increases in depreciation expense
on production equipment purchased for $1,850,680 and put into service.
Amortization and depreciation expense was $88,688 for the three months
ended December 31, 1998 compared to $19,981 for the three months ended December
31, 1997. The 343.9% increase was attributable for the same reasons set forth in
the six months analysis.
Research and Development Expenses
---------------------------------
Research and development expense increased 45.3% to $217,016 during the six
months ended December 31, 1998 from $149,310 during the six months ended
December 31, 1997. The increase is primarily attributable to stock based bonuses
given to two of the officers for deferring salaries so the Company could use
these funds as working capital.
Research and development expense increased 80.4% to $135,625 during the
three-month period ended December 31, 1998 from $75,200 during the three months
ended December 31, 1997 for primarily the same reasons set forth in the
six-month analysis.
Interest Expense
----------------
Interest expense was $89,618 for the six months ended December 31, 1998
compared to $92,069 for the six months ended December 31, 1997. The 2.7%
decrease was attributable to the reduction on the short-term debt margin loan,
offset, in part, by interest expense on increased short-term loans and officer
loans.
Interest expense was $49,079 for the three months ended December 31, 1998
compared to $45,398 for the three months ended December 31, 1997. the 8.2%
increase was attributable to imputed interest on stock issued in consideration
for short-term loans.
-17-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)
--------------------------------------------------
Liquidity and Capital Resources
-------------------------------
The Company's need for funds has increased from period to period as it has
incurred expenses for among other things, research and development; applications
for domestic and international trademarks and international patent protection;
licensing and pre-marketing activities; and attempts to raise the necessary
capital for initial production. Since inception, the Company has funded these
needs through private placements of its equity and debt securities and advances
from Mr. Zsigmond Sagi ("Sagi"), the Company's President, Chief Executive
Officer and major shareholder. The Company has entered into various license
agreements that have raised additional funds and borrowed money against common
stock received in connection with the license agreements. In addition, the
Company's auditors' report for the year ended June 30, 1998 dated September 1,
1998, expressed an opinion as to the Company continuing as a going concern.
During September 1998, the Company commenced the sale of its BreastCare(TM)
device in Brazil, Uruguay and Paraguay through its South American licensee. The
Company expects to expand its distribution and be fully operational during the
first quarter of calendar 1999. However, until that time, the Company needs
financing to fund its current overhead and various capital requirements. As of
December 31, 1998, the Company borrowed $300,000 from unaffiliated third
parties, and in December 1998 the Company borrowed an additional $100,000 from a
director of the Company. These loans are payable by the Company in early 1999.
In addition, Sagi advanced the Company an additional $184,000 during the first
and second quarters of its fiscal year. These loans will support the Company
through the first quarter of 1999, and the Company expects the cash flow from
sales commencing in 1999 to cover the operations of the Company over the balance
of the fiscal year providing the Company is successful in raising the initial
capital.
The Company's working capital and capital requirements will depend on
numerous factors, including the level of resources that the Company devotes to
the purchase of manufacturing equipment to support start-up production and to
the marketing aspects of its products. The Company intends to construct
production and/or assembly centers abroad to manufacture, market and sell the
BreastCare(TM) in the international market. The Company entered into an
agreement with Zigmed Inc. pursuant to which manufacturing of the BreastCare(TM)
for the contract price of $1,850,680. The Company as of December 31, 1998, has
advanced Zigmed Inc. payments of $800,000 and in September 1996 issued Zigmed
Inc. 100,000 shares of the Company's common stock (valued at $1.00 per share)
against the contract price. The balance of $950,680 will be paid when the
Company raises the additional capital.
The Company has also executed a letter of intent with respect to the
acquisition of a Hungarian based manufacturer of plastic medical packaging
products and the manufacturing facility for an aggregate purchase price of
$1,750,000. The acquisition is subject to the Company obtaining financing for
the purchase of the Hungarian manufacturer.
-18-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)
-------------------------------------------------
The Company entered into an exclusive license agreement, dated September
22, 1997, and amended February 18, 1998, with Sandell Corp. S.A. (the "Sandell
Agreement"), a Uruguayan corporation ("Sandell"), pursuant to which the Company
granted to Sandell an exclusive license to market and distribute the product in
Brazil, Venezuela, Columbia, Costa Rica, Ecuador, Nicaragua, Paraguay, Panama,
Peru, Bolivia, Argentina and Uruguay. Sandell is required to maintain operations
in Uruguay's Free Trade Zone. The Sandell Agreement is for a term of fourteen
(14) years. Under the Sandell Agreement, Sandell is to pay the Company a
non-refundable license fee of (i) $500,000 and (ii) thirty-five (35%) percent of
the outstanding shares of Sandell on a fully diluted basis. The cash portion of
the fee is payable: (i) $100,000 upon execution of the Sandell Agreement, which
was paid by Sandell on October 14, 1997; (ii) $200,000 forty-five (45) days
after shipment of the first product in 1999, and (iii) $200,000 on or before
January 30, 2000. Sandell is also required to make minimum purchases of the
BreastCare(TM) as follows: (i) 20,000 units per month during the first six
months of calendar 1999 (ii) 35,000 units per month during the balance of 1999,
(iii) 65,000 units during 2000, and (iv) 90,000 units per month during 2001 and
thereafter during the term of the license.
On August 15, 1996, the Company entered into a license agreement with
Health Technologies International Inc. ("HTI"), whereby HTI is to assemble,
market and sell the BreastCare(TM) in Chile and Singapore and pay the Company a
licensing fee of $250,000, all of which has been received. HTI was acquired by
D-Lanz Development Group, Inc. ("D-Lanz") in November 1997. As part of the
licensing agreement, the Company received 2,000,000 shares of D-Lanz common
stock which is publicly traded on the Electronic Bulletin Board under the symbol
DLNZ. Pursuant to the terms of the agreement, HTI agreed to pay the Company
minimum royalties of $100,000 in 1999 with increasing royalties leveling out at
a minimum of $400,000 in the year 2000 and thereafter. D-Lanz has signed a
letter of intent for Sandell to distribute the BreastCare(TM) in Chile.
The Company and HumaScan Inc. ("HumaScan"), its original licensee in the
United States and Canada, have reached a settlement agreement dated May 15,
1998, resolving certain disputes which have arisen under the licensee agreement.
Among the many issues that were resolved, the following was agreed upon
concerning the licensing fee and royalties:
In consideration for a paid-up license and the prior delivery of
technological know-how, consulting services and product development activities,
the licensee agreed to pay the Company $575,000 on various dates through
December 31, 1999, of which $175,000 was received upon signing the agreement,
and issue the Company 400,000 warrants exercisable at $4.725 per share vesting
on various dates through March 31, 1999 and having a term of five (5) years from
date of vesting.
-19-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)
-------------------------------------------------
In connection with the agreement, commencing with the first day of the
first month in which the Licensed Product is sold and for each year through and
including the termination date October 20, 2012, the Licensee agrees to pay the
Company a royalty based on net sales as follows: three (3%) percent of the first
$2 million of net sales increasing to ten (10%) percent of net sales in excess
of $10 million with a minimum royalty of $400,000 in the third year increasing
to $600,000 in the fifth year and thereafter. The earned royalties payable shall
be reduced by an amount of up to a maximum of $550,000 at the rate of $.50 for
each dollar of earned royalty payable until the amount of $550,000 has been
deducted.
During November 1998, HumaScan issued a statement concerning the ability of
the Company to continue as a going concern. As of this date, all payments due
the Company from HumaScan have been received, except for a $75,000 payment due
December 31, 1998. The Company is concerned regarding the U.S. Licensee's
operations and the expected royalty payments due the Company. The Company owns
approximately 650,000 shares of HumaScan common stock. The drop in value of the
common stock of HumaScan owned by the Company has been reflected on the
Company's balance sheet at December 31, 1998.
The Company's success is dependent on raising sufficient capital to
establish a production and assembly facility and purchase additional
manufacturing equipment to manufacture the BreastCare(TM) for the international
market. The Company does not have all the financing in place at this time, nor
may it ever, to meet these objectives. The Company believes the BreastCare(TM)
will be commercially accepted throughout the international market.
As stated previously, the Company has financed its operations through
private placements of its equity and debt securities and advances from the
Company's President.
In a 1994 private placement, the Company raised $246,000 through unsecured
notes. Each noteholder received 2,000 shares of the Company's common stock as
additional consideration for their ten (10%) percent promissory note. The
promissory notes issued in connection with these bridge loans are due in full
upon the completion of a public offering by the Company. In March 1995, the
Company offered to convert the promissory notes into shares of the Company's
common stock at a conversion price of $1.00 per share. $121,000 of the notes
were converted including accrued interest of $30,084. As of December 31, 1997,
all remaining notes have been paid.
On June 30, 1996, the Company consolidated a $288,006 note, due June 30,
1996 and a $600,000 note, due August 20, 1996, into one note for $888,006
bearing simple interest at ten (10%) percent per year. The Company has
renegotiated the note with the lenders as of March 31, 1998. The note is due
September 30, 2000; all remaining notes have been paid.
In July and August 1996, the Company completed two private placements of
the Company's common stock, raising proceeds of $1,070,000.
-20-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)
-------------------------------------------------
During May 1998, the Company was obligated on its short-term debt to repay
approximately $900,000. The common stock of HumaScan owned by the Company
pledged as collateral for the loan fell below $3.00 per share requiring the
Company either to sell the HumaScan shares or use alternative means to liquidate
the short-term debt. The Company sold marketable securities other than the
HumaScan stock, sold approximately 120,000 shares of HumaScan stock, and the
balance of the funds to liquidate the debt of approximately $317,000 was
advanced by Sagi.
This Management's Discussion and Analysis of Financial Condition and
Results of Operations includes forward-looking statements that may or may not
materialize. Additional information on factors that could potentially affect the
Company's financial results may be found in the Company's filings with the
Securities and Exchange Commission.
Other Matters
- --------------
Year 2000
Background
- ----------
The Year 2000 problem is the result of computer programs being written
using two digits (rather than four) to define the applicable years. Any of the
Company's programs that have time-sensitive software may recognize a date using
"00" as the year 1900 rather than the year 2000, which could result in
miscalculations or system failures.
The Company will rely heavily on computer technologies to operate its
business. In 1998, the Company conducted an initial assessment of its
information technology to determine which Year 2000 related problems might cause
processing errors or computer system failures. The Company also did a complete
analysis of its present computer system and its needs for the future. Based on
the results of that analysis, the Company's executive management identified the
Year 2000 problem as a top corporate priority and established an internal group
to provide a solution.
The following discussion of the implications of the Year 2000 problem for
the Company contains numerous forward-looking statements based on inherently
uncertain information. The cost of the project and the date on which the Company
plans to complete its internal Year 2000 modifications are based on the
Company's best estimates, which were derived utilizing a number of assumptions
of future events including the continued availability of internal and external
resources, third party modifications and other factors. However, there can be no
guarantee that these estimates will be achieved, and actual results could
differ. Moreover, although the Company believes it will be able to make the
necessary modifications in advance, there can be no guarantee that failure to
modify the systems would not have a material adverse effect on the Company.
-21-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
In addition, the Company places a high degree of reliance on computer
systems of third parties, such as customers, trade suppliers and computer
hardware and commercial software suppliers. Although the Company is assessing
the readiness of these third parties and preparing contingency plans, there can
be no guarantee that the failure of these third parties to modify their systems
in advance of December 31, 1999, would not have a material adverse effect on the
Company.
Readiness
- ---------
The Year 2000 project is intended to ensure that all critical systems,
devices and applications, as well as data exchanged with customers, trade
suppliers and other third parties have been evaluated and will be suitable for
continued use into and beyond the Year 2000.
The Company is a development stage company and expects to be fully
operational in early 1999. All computers the Company operates now are compatible
with the Year 2000. The Company expects to vastly upgrade its computer system as
it becomes fully operational in 1999.
Since early 1998, the Company has required Year 2000 compliance statements
from all suppliers of the Company's computer hardware and commercial software.
Regardless of the compliance statements, all third party hardware and software
will also be subjected to testing to reconfirm the Year 2000 readiness.
Cost
- ----
The Company estimates that the total cost of achieving Year 2000 readiness
for its internal systems, devices and applications and a complete upgrade of its
computer system is approximately $250,000. The cost of the Year 2000 problem is
not material but the extent of upgrading the computer system will absorb most of
the cost. Year 2000 project costs are difficult to estimate accurately, and the
projected cost could change due to unanticipated technological difficulties and
Year 2000 readiness of third parties.
Contingency Plans
- -----------------
In the event that the efforts of the Company's Year 2000 project do not
address all potential systems problems, the Company is currently developing
business interruption contingency plans. The Company believes, however, that due
to the widespread nature of potential Year 2000 issues, the contingency planning
process is an ongoing one which will require further modifications as the
Company obtains additional information regarding (1) the Company's internal
systems during the remediation and testing phases of its Year 2000 project and
(2) the status of third party Year 2000 readiness. Contingency planning for
possible Year 2000 disruptions will continue to be defined, improved and
implemented.
-22-
<PAGE>
SCANTEK MEDICAL INC. AND SUBSIDIARY
(DEVELOPMENT STAGE COMPANIES)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Risks
- -----
The Company believes that completed and planned modifications and
conversions of its critical systems, devices and applications will allow it to
be Year 2000 compliant in a timely manner. There can be no assurances, however,
that the Company's internal systems, devices and applications or those of a
third parties on which the Company relies will be Year 2000 compliant by year
2000 or that the Company's or third parties' contingency plans will mitigate the
effects of any noncompliance. An interruption of the Company's ability to
conduct its business due to a Year 2000 readiness problem could have a material
adverse effect on the Company.
This report contains forward-looking statements that involve substantial
risks and uncertainties. The Company's actual results could differ materially
from those discussed herein. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed in the "Business,"
"Management's Discussion and Analysis of Financial Condition and Results of
Operations," and "Risks and Uncertainties" captions in the Company's Form 10-KSB
for the year ended June 30, 1998.
-23-
<PAGE>
PART II. Other Information
Item 1. Legal Proceedings
-----------------
See Item 3 of the Company's Form 10-KSB for the year ended June 30, 1998.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits: Exhibit 27.1 Financial Data Schedule.
(b) There were no Current Reports on Form 8-K filed by the registrant
during the quarter ended December 31, 1998.
-24-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
SCANTEK MEDICAL INC.
By: /s/ ZSIGMOND SAGI
----------------------------------
Zsigmond Sagi, President and
Chief Financial Officer
Dated: February 15, 1999
-25-
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM SCANTEK
MEDICAL INC. FINANCIAL STATEMENTS AT DECEMBER 31, 1998 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> JUN-30-1999
<PERIOD-END> DEC-31-1998
<CASH> 32,278
<SECURITIES> 641,678
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 159,132
<CURRENT-ASSETS> 1,537,662
<PP&E> 1,996,259
<DEPRECIATION> 111,012
<TOTAL-ASSETS> 3,790,043
<CURRENT-LIABILITIES> 3,714,581
<BONDS> 0
<COMMON> 17,945
0
0
<OTHER-SE> (830,489)
<TOTAL-LIABILITY-AND-EQUITY> 3,790,043
<SALES> 0
<TOTAL-REVENUES> 880,410
<CGS> 97,809
<TOTAL-COSTS> 720,900
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 89,618
<INCOME-PRETAX> (27,917)
<INCOME-TAX> 0
<INCOME-CONTINUING> (27,917)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (27,917)
<EPS-PRIMARY> .00
<EPS-DILUTED> .00
</TABLE>
